Literature DB >> 1541687

Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey.

M F Laker1, J P Reckless, D J Betteridge, P N Durrington, J P Miller, D P Nicholls, J Shepherd, G R Thompson.   

Abstract

AIMS: To determine the availability of facilities for the investigation of hyperlipidaemia in the United Kingdom.
METHODS: A questionnaire was sent to all health districts in the United Kingdom.
RESULTS: The response rate was 81%. All laboratories used enzymatic techniques to measure serum triglyceride and cholesterol concentrations, although there were differences in standardisation procedures. Reference ranges for serum lipids were quoted by 58% of laboratories while 50% quoted "desirable limits". Almost half specified that fasting blood samples were required. High density lipoprotein cholesterol concentrations were estimated by 75% and apolipoproteins AI and B by 14% of laboratories; there were differences in specimen type and considerable diversity in procedures used for measurement.
CONCLUSIONS: Many laboratories were unaware of current recommendations for screening for hypercholesterolaemia in the community. The present survey indicated an urgent need for the introduction of better reference methods, standardisation, and quality assurance procedures before apolipoproteins become a routine part of coronary heart disease risk assessment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541687      PMCID: PMC495645          DOI: 10.1136/jcp.45.2.102

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

Review 1.  Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis.

Authors:  A D MBewu; P N Durrington
Journal:  Atherosclerosis       Date:  1990-11       Impact factor: 5.162

2.  Apolipoproteins AI, AII and B in young adults: associations with CHD risk factors. The Beaver County experience.

Authors:  R P Donahue; T J Orchard; E A Stein; L H Kuller
Journal:  J Chronic Dis       Date:  1986

3.  Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association.

Authors:  J Shepherd; D J Betteridge; P Durrington; M Laker; B Lewis; J Mann; J P Miller; J P Reckless; G R Thompson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-14

4.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

5.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

6.  Lipid screening: is it enough to measure total cholesterol concentration?

Authors:  H A Neil; D Mant; L Jones; B Morgan; J I Mann
Journal:  BMJ       Date:  1990-09-22

7.  Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.

Authors:  E A Nikkilä; P Viikinkoski; M Valle; M H Frick
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-28

8.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

9.  Minimizing interlaboratory variation in routine assays of serum cholesterol through the use of serum calibrators.

Authors:  G J Boerma; A P Jansen; R T Jansen; B Leijnse; R van Strik
Journal:  Clin Chem       Date:  1986-06       Impact factor: 8.327

10.  Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease.

Authors:  P N Durrington; M Ishola; L Hunt; S Arrol; D Bhatnagar
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

View more
  3 in total

1.  Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

Authors:  D J Betteridge; P M Dodson; P N Durrington; E A Hughes; M F Laker; D P Nicholls; J A Rees; C A Seymour; G R Thompson; A F Winder
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

2.  Triglyceride concentration and coronary heart disease. Routine measurement is justified.

Authors:  P H Winocour
Journal:  BMJ       Date:  1994-09-10

3.  Hypercholesterolaemia: not all cases warrant treatment.

Authors:  J Patmore; S Coyle; R Jones; G Wieringa
Journal:  BMJ       Date:  1993-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.